Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary endpoints were metResults presented today at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting WATERTOWN, Mass., Feb.

亚组分析强调了EYP-1901的良好临床特征和持久性。陈述强调了先前报道的阳性2期DAVIO 2 topline结果，显示所有主要和次要终点都是今天在马萨诸塞州沃特敦2024年虚拟会议上提出的测量结果。

03, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced results from new subgroup analyses from the Phase 2 DAVIO 2 clinical trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E.

2024年3月3日（环球通讯社）--EyePoint Pharmaceuticals，Inc.（纳斯达克：EYPT），一家致力于开发和商业化治疗药物以改善严重视网膜疾病患者的生活的公司，今天宣布了EYP-1901的2期DAVIO 2临床试验的新亚组分析结果，一项针对湿性年龄相关性黄斑变性（湿性AMD）的研究性持续递送维持治疗，将选择性酪氨酸激酶抑制剂沃罗拉尼与生物可利用的Durasert E结合使用。

These data are being presented in two sessions at the Angiogenesis, Exudation, and Degeneration 2024 Meeting held virtually today, February 3, 2024. The presenting speakers are Charles C. Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas, and Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University.

这些数据将在今天（2024年2月3日）举行的2024年血管生成，渗出和退化会议上分两次提交。主讲人是德克萨斯州视网膜顾问研究主任Charles C.Wykoff医学博士和托马斯·杰斐逊大学眼科教授Carl Regillo医学博士FACS。

“The findings from these subgroup analyses reinforce the highly favorable clinical profile of EYP-1901 and its potential to be a paradigm-altering maintenance treatment for patients with wet AMD,” said Jay Duker, M.D., Chief Executive Officer of EyePoint Pharmaceuticals. “The data demonstrated that in the subgroup analysis of patients that were supplement free up to 6 months, patients that received EYP-1901 demonstrated numerical superiority in change in best corrected visual acuity (BCVA) as well as anatomic stability compared to aflibercept.

EyePoint Pharmaceuticals首席执行官杰伊·杜克（JayDuker）医学博士说：“这些亚组分析的结果强化了EYP-1901的高度有利的临床特征及其成为湿性AMD患者改变维持治疗模式的潜力。”。“数据表明，在长达6个月的无补充剂患者的亚组分析中，与阿柏西普相比，接受EYP-1901治疗的患者在最佳矫正视力（BCVA）变化以及解剖稳定性方面表现出数字优势。

This result confirms that the positive visual and anato.

这一结果证实了积极的视觉和解剖。